Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $41
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $37 to $41.
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $37 to $41.